The potential acquisition comes as part of the company's strategic growth plan to further invest in specialty ingredient capabilities and diversify its portfolio of solutions.
The acquisition includes the manufacturing, marketing and distribution of WK Kellogg Co's portfolio of breakfast cereals across the United States, Canada and the Caribbean.
The Akkermansia Company has patents protecting the use of the Akkermansia species, including the use of the MucT strain’s pasteurized version, which is its most bio-efficacious form.
The proposed $36 billion acquisition has received all but one of 28 required regulatory clearances. Antitrust review by the European Commission is ongoing.